scholarly journals Pathogenic role of CXCR7 in rheumatoid arthritis

2010 ◽  
Vol 62 (11) ◽  
pp. 3211-3220 ◽  
Author(s):  
Kaori Watanabe ◽  
Mark E. T. Penfold ◽  
Akio Matsuda ◽  
Naho Ohyanagi ◽  
Kayoko Kaneko ◽  
...  
2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 854.2-854
Author(s):  
Y.J. Kim ◽  
E.-J. Lee ◽  
S. Hong ◽  
B.S. Koo ◽  
W.J. Seo ◽  
...  

Arthritis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Atsushi Ogata ◽  
Atsushi Kumanogoh ◽  
Toshio Tanaka

Psoriatic arthritis (PsA) is a clinical manifestation of psoriatic disease. Although the pathogenesis of PsA remains unknown, PsA can be managed by treatments similar to those used for rheumatoid arthritis (RA). Because interleukin-(IL-) 6 has been suggested to have a pathogenic role in PsA, a humanized anti-IL-6 receptor antibody tocilizumab treatment for PsA was recently tried. However, the efficacy of tocilizumab for PsA was not favorable. This suggests that the pathogenic roles of IL-6 in PsA and RA are different. In RA, tumor necrosis factor (TNF) primarily contributes to the arthritis effector phase and IL-6 contributes to the arthritis priming phase. In PsA, the TNF-related effector phase is similar to that in RA, but the IL-6-related priming phase might not be critical. This paper discusses the role of IL-6 in PsA.


2006 ◽  
Vol 2 (3) ◽  
pp. 365-375 ◽  
Author(s):  
Andrew J Kinloch ◽  
Karin E Lundberg ◽  
David Moyes ◽  
Patrick J Venables

Angiogenesis ◽  
2015 ◽  
Vol 18 (4) ◽  
pp. 433-448 ◽  
Author(s):  
Hatem A. Elshabrawy ◽  
Zhenlong Chen ◽  
Michael V. Volin ◽  
Shalini Ravella ◽  
Shanti Virupannavar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document